Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Innoviva Inc (INVA)

Innoviva Inc (INVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,478,183
  • Shares Outstanding, K 74,769
  • Annual Sales, $ 358,710 K
  • Annual Income, $ 23,390 K
  • EBIT $ 181 M
  • EBITDA $ 223 M
  • 60-Month Beta 0.47
  • Price/Sales 4.07
  • Price/Cash Flow 5.70
  • Price/Book 1.44

Options Overview Details

View History
  • Implied Volatility 69.04% (+4.73%)
  • Historical Volatility 19.18%
  • IV Percentile 71%
  • IV Rank 26.25%
  • IV High 182.55% on 09/15/25
  • IV Low 28.63% on 06/02/25
  • Expected Move (DTE 22) 1.11 (5.59%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 228
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,672
  • Open Int (30-Day) 6,333
  • Expected Range 18.67 to 20.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.34
  • Number of Estimates 2
  • High Estimate 0.48
  • Low Estimate 0.19
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -40.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.30 +2.43%
on 12/24/25
22.16 -10.79%
on 11/26/25
-1.52 (-7.14%)
since 11/24/25
3-Month
16.52 +19.67%
on 10/15/25
22.76 -13.14%
on 11/13/25
+0.83 (+4.38%)
since 09/24/25
52-Week
16.52 +19.67%
on 10/15/25
22.76 -13.14%
on 11/13/25
+1.99 (+11.19%)
since 12/24/24

Most Recent Stories

More News
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence...

INVA : 19.77 (+1.33%)
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive...

INVA : 19.77 (+1.33%)
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva...

INVA : 19.77 (+1.33%)
Innoviva: Q3 Earnings Snapshot

Innoviva: Q3 Earnings Snapshot

INVA : 19.77 (+1.33%)
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth ...

INVA : 19.77 (+1.33%)
Antheia Appoints Eric d'Esparbes as Chief Financial Officer

d'Esparbes to lead Antheia's financial strategy as the company continues its global expansion and commercialization

INVA : 19.77 (+1.33%)
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial

INVA : 19.77 (+1.33%)
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Highlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment for uncomplicated gonorrhea due to Neisseria...

INVA : 19.77 (+1.33%)
Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva...

INVA : 19.77 (+1.33%)
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that two of the company’s infectious disease therapies, ZEVTERA ® (ceftobiprole medocaril...

INVA : 19.77 (+1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

3rd Resistance Point 20.70
2nd Resistance Point 20.32
1st Resistance Point 20.05
Last Price 19.77
1st Support Level 19.40
2nd Support Level 19.02
3rd Support Level 18.75

See More

52-Week High 22.76
Fibonacci 61.8% 20.38
Last Price 19.77
Fibonacci 50% 19.64
Fibonacci 38.2% 18.90
52-Week Low 16.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar